Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

This activity was originally broadcast in conjunction with AMCP 2024.

Program Description

Generalized pustular psoriasis (GPP) and localized palmoplantar pustular psoriasis (PPP) are rare subtypes of psoriasis characterized by recurrent outbreaks of pustules and inflammation on the skin’s surface. Studies show biologic therapies are more effective than nonbiologic therapies in the treatment of these disease states, with novel targeted therapies evaluated specifically for use in GPP and PPP. These diseases impact quality of life through economic, physical, and psychological burden. They also result in higher rates of health care resource utilization, which negatively affect both people living with GPP or PPP and health care systems. A lack of awareness surrounding the distinctions between GPP, PPP, and other forms of psoriasis may lead to an incorrect or delayed diagnosis, which can result in life-threatening complications. Managed care pharmacists can prevent misdiagnosis by educating clinicians and patients on the nuances of these diseases. They can also bridge gaps in care by providing patients access to GPP-specific treatments and biologics when available. This activity includes an overview of the clinical presentation, economic challenges, and potential treatment options associated with GPP. Managed care pharmacists need education on recent clinical data surrounding GPP and PPP so they can support patients in shared decision making, promote access and adherence to treatments, and allocate resources accordingly.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: May 3, 2024
Expiration date: July 24, 2025

Time to complete activity: 1.5 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical and economic burden associated with generalized pustular psoriasis (GPP).
• Analyze the evidence-based approach to care for the treatment of GPP and palmoplantar pustular psoriasis (PPP), as well as clinical data on available and emerging biologic therapies.
• Explore the managed care role in facilitating appropriate access to novel agents to improve clinical outcomes and health care resource utilization associated with the management of pustular psoriasis.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-122-H01-P. The activity is available for CE credit through July 24, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Geoffrey Wall, PharmD, has the following financial relationship with a commercial interest to disclose:

Speakers Bureau: Janssen Pharmaceuticals

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Libbi Green, PharmD

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms